A Phase 1 interventional study of Cytisine in Smoking Cessation, sponsored by Achieve Life Sciences. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-26.
Sponsored by Achieve Life Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.
Among the 22 studies testing cytisine in Smoking Cessation, this one is the 19th largest by enrollment, is one of 3 that started in 2017, is one of 6 in phase 1, and was the 3rd registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health
Ages 18+
Maimónides Biomedical Research Institute of Córdoba
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 7 · Phase 4 3
First in 2016; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 202 across the 22 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
Achieve Life Sciences is the lead sponsor of 31 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 8 (67%) have results posted.
10 studies in Smoking Cessation by Achieve Life Sciences: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Smoking Cessation by Achieve Life Sciences, this one is the 9th largest by enrollment, is one of 2 that started in 2017, is one of 5 in phase 1, and was the 1st registered.
Achieve Life Sciences’s Smoking Cessation studies by the year they started, since 2017.
1 of the studies testing cytisine in Smoking Cessation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06617312University of California, Los AngelesExamining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing cytisine in Smoking Cessation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Achieve Life Sciences’s 10 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This will be an open-label, randomised, 2-period, single-dose crossover study to determine the comparative bioavailability of cytisine following single-dose administration in healthy male and female subjects under fed and fasted conditions.
The study will be comprised of a pre-study screen, followed by 2 treatment periods (1 and 2) and a post-study follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy males and females between 18 and 55 years of age.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Schedule A (12 subjects): * Period 1: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state). * Period 2: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state).
Drug: Cytisine
Schedule B (12 subjects): * Period 1: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state). * Period 2: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state).
Drug: Cytisine
Cytisine 1.5 mg Film-Coated Tablets
Also known as: Tabex
Plasma Cytisine Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)
Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Plasma Cytisine PK: Total Area Under the Curve From Time Zero to Infinity (AUC0-∞)
Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Plasma Cytisine PK: Time of Occurrence of Cmax (Tmax)
Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Plasma Cytisine PK: AUC From Time Zero to the Last Sampling Time (AUC0-t)
Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Plasma Cytisine PK: Residual Area, or Percentage of Extrapolated Part for the Calculation of AUC0-∞ (AUC%)
Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Plasma Cytisine PK: Apparent Terminal Elimination Rate Constant (Lambda z)
Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Plasma Cytisine PK: Apparent Terminal Elimination Half-Life (t1/2)
Time frame: Pre-dose (within 60 minutes of dosing); 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours and 24 hours post-dose (+/- 1 minute)
Urine Cytisine PK: Amount Excreted in Urine Over Time (Ae)
Time frame: Pre-dose (within 30 minutes prior to first dose); 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours and 12-24 hours post-dose
Urine Cytisine PK: Percentage of Drug Excreted in Urine (Ae%)
To assess the renal elimination of cytisine via measurement of urinary concentrations of cytisine.
Time frame: Pre-dose (within 30 minutes prior to first dose); 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours and 12-24 hours post-dose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuation of Study Drug Due to AEs, by Severity and Relationship
An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have a causal relationship with the treatment. TEAEs are defined as AEs not present prior to first administration of investigational product, or AEs present before first administration of study drug that worsen after the subject receives the first dose of study drug. A serious adverse event (SAE) is defined as an AE that: results in death; is life-threatening; requires hospitalization or prolongs existing inpatient's hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event which requires medical intervention to prevent any of the above outcomes. Event severity was categorized as mild, moderate, or severe. Relationship of event to study drug was categorized as definite, probably, possible, unlikely, not related, or not applicable (N/A).
Time frame: Day -1 to Day 7 plus 6-8 days (post-study follow-up)
| Milestone | 3 mg Cytisine, Schedule A: Fed Then Fasted | 3 mg Cytisine, Schedule B: Fasted Then Fed |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| ng/mL | 3 mg Cytisine, Fed | 3 mg Cytisine, Fasted |
|---|---|---|
| Plasma Cytisine Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) | 22.9 ± 5.44 | 30.8 ± 7.91 |
| h*ng/mL | 3 mg Cytisine, Fed | 3 mg Cytisine, Fasted |
|---|---|---|
| Plasma Cytisine PK: Total Area Under the Curve From Time Zero to Infinity (AUC0-∞) | 170 ± 30.3 | 176 ± 33.1 |
| hours | 3 mg Cytisine, Fed | 3 mg Cytisine, Fasted |
|---|---|---|
| Plasma Cytisine PK: Time of Occurrence of Cmax (Tmax) | 2.75 (0.500 to 6.12) | 0.75 (0.333 to 3.00) |
| h*ng/mL | 3 mg Cytisine, Fed | 3 mg Cytisine, Fasted |
|---|---|---|
| Plasma Cytisine PK: AUC From Time Zero to the Last Sampling Time (AUC0-t) | 163 ± 29.4 | 169 ± 33.0 |
| percentage of extrapolated part | 3 mg Cytisine, Fed | 3 mg Cytisine, Fasted |
|---|---|---|
| Plasma Cytisine PK: Residual Area, or Percentage of Extrapolated Part for the Calculation of AUC0-∞ (AUC%) | 4.37 ± 1.40 | 3.85 ± 1.46 |
| 1/hour | 3 mg Cytisine, Fed | 3 mg Cytisine, Fasted |
|---|---|---|
| Plasma Cytisine PK: Apparent Terminal Elimination Rate Constant (Lambda z) | 0.154 ± 0.0391 | 0.156 ± 0.0314 |
| hours | 3 mg Cytisine, Fed | 3 mg Cytisine, Fasted |
|---|---|---|
| Plasma Cytisine PK: Apparent Terminal Elimination Half-Life (t1/2) | 4.77 ± 1.16 | 4.59 ± 0.832 |
| mg | 3 mg Cytisine, Fed | 3 mg Cytisine, Fasted |
|---|---|---|
| Urine Cytisine PK: Amount Excreted in Urine Over Time (Ae) | 2.59 ± 0.407 | 2.47 ± 0.357 |
To assess the renal elimination of cytisine via measurement of urinary concentrations of cytisine.
| percentage of drug excreted | 3 mg Cytisine, Fed | 3 mg Cytisine, Fasted |
|---|---|---|
| Urine Cytisine PK: Percentage of Drug Excreted in Urine (Ae%) | 86.5 ± 13.6 | 82.4 ± 11.9 |
An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have a causal relationship with the treatment. TEAEs are defined as AEs not present prior to first administration of investigational product, or AEs present before first administration of study drug that worsen after the subject receives the first dose of study drug. A serious adverse event (SAE) is defined as an AE that: results in death; is life-threatening; requires hospitalization or prolongs existing inpatient's hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event which requires medical intervention to prevent any of the above outcomes. Event severity was categorized as mild, moderate, or severe. Relationship of event to study drug was categorized as definite, probably, possible, unlikely, not related, or not applicable (N/A).
| participants | 3 mg Cytisine, Fed | 3 mg Cytisine, Fasted |
|---|---|---|
| ≥ 1 TEAE | 6 | 7 |
| ≥ 1 Serious TEAE | 0 | 0 |
| ≥ 1 TEAE Leading to Withdrawal of Study Drug | 0 | 0 |
| ≥ 1 Mild TEAE | 6 | 7 |
| ≥ 1 Moderate TEAE | 0 | 0 |
| ≥ 1 Severe TEAE | 0 | 0 |
| ≥ 1 TEAE Definitely Related to Study Drug | 0 | 0 |
| ≥ 1 TEAE Probably Related to Study Drug | 1 | 1 |
| ≥ 1 TEAE Possibly Related to Study Drug | 3 | 5 |
| ≥ 1 TEAE Unlikely Related to Study Drug | 1 | 1 |
| ≥ 1 TEAE Not Related to Study Drug | 0 | 0 |
| ≥ 1 TEAE Relationship to Study Drug = N/A | 1 | 0 |
Collected over Day -1 to Day 7 plus 6-8 days (post-study follow-up). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3 mg Cytisine, Fed | 0/24 (0%) | 0/24 (0%) | 6/24 (25%) |
| 3 mg Cytisine, Fasted | 0/24 (0%) | 0/24 (0%) | 7/24 (29.2%) |
| 3 mg Cytisine, Overall | 0/24 (0%) | 0/24 (0%) | 10/24 (41.7%) |
| Event | 3 mg Cytisine, Fed | 3 mg Cytisine, Fasted | 3 mg Cytisine, Overall |
|---|---|---|---|
| DizzinessNervous system disorders | 2/24 | 3/24 | 4/24 |
| VomitingGastrointestinal disorders | 2/24 | 1/24 | 3/24 |
| HeadacheNervous system disorders | 2/24 | 2/24 | 3/24 |
| NauseaGastrointestinal disorders | 1/24 | 1/24 | 2/24 |
| Abdominal pain lowerGastrointestinal disorders | 0/24 | 1/24 | 1/24 |
| Feeling hotGeneral disorders | 0/24 | 1/24 | 1/24 |
| RhinitisInfections and infestations | 1/24 | 0/24 | 1/24 |
| HypoaesthesiaNervous system disorders | 1/24 | 0/24 | 1/24 |
| SomnolenceNervous system disorders | 0/24 | 1/24 | 1/24 |
| Cold sweatSkin and subcutaneous tissue disorders | 1/24 | 0/24 | 1/24 |
| Age, Continuous(years) | 3 mg Cytisine |
|---|---|
| Mean | 35.1 ± 10.25 |
| Sex: Female, Male(Participants) | 3 mg Cytisine |
|---|---|
| Female | 13 |
| Male | 11 |
| Race/Ethnicity, Customized(Participants) | 3 mg Cytisine |
|---|---|
| Caucasian | 23 |
| Other, Not Specified | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Aug 2017 to primary completion in Aug 2017, 0 months.
Results were first posted in Feb 2019, 1 year 5 months after primary completion.
Of 34 phase 1 interventional studies under Smoking Cessation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 34. This study's 0 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cytisine